Italian venture capital firm Panakès Partners, previously active in medtech, has closed the €150m purple fund with the goal to invest in underserved European Life Science companies.
https://european-biotechnology.com/wp-content/uploads/2024/04/panakes-fabrizio.jpg15552048Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2021-07-22 08:00:002021-07-22 08:00:00Panakès expands into biotech with €150m fund
Mainz-based BioNTech is expanding its portfolio for cancer therapies with theneoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals.
https://european-biotechnology.com/wp-content/uploads/2024/04/biontech-20210719.jpg12801920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-07-20 08:00:002021-07-20 08:00:00BioNTech takes over cancer immunotherapy platform
Dutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers.
https://european-biotechnology.com/wp-content/uploads/2024/04/coins-1726618_1920.jpg12791920Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2021-07-15 07:00:002021-07-15 07:00:00€26m financing for ISA Pharmaceuticals
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2021-07-13 11:19:172021-07-13 11:19:17Nordic Nanovector with Interim CEO
Danish Novo Nordisk is moving out of the diabetes space and taking over Prothena’s ATTR amyloidosis programme – including a Phase II-ready immunotherapy.
Synaffix inks $246m deal with ProfoundBio
Latest NewsSynaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Panakès expands into biotech with €150m fund
Latest NewsItalian venture capital firm Panakès Partners, previously active in medtech, has closed the €150m purple fund with the goal to invest in underserved European Life Science companies.
BioNTech takes over cancer immunotherapy platform
Latest NewsMainz-based BioNTech is expanding its portfolio for cancer therapies with the neoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals.
Nanosyrinx raises £6.2m to validate drug delivery platform
Latest NewsCoventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.
€26m financing for ISA Pharmaceuticals
Latest NewsDutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers.
Unilever licences Arzeda Inc.s enzyme technology
Latest NewsAs part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon.
Nordic Nanovector with Interim CEO
AppointmentsMalene Brondberg, Chief Financial Officer of Nordic Nanovector since May 2020, became Interim Chief Executive Officer of the company.
Novo Nordisk invests in amyloidosis pipeline
Latest NewsDanish Novo Nordisk is moving out of the diabetes space and taking over Prothena’s ATTR amyloidosis programme – including a Phase II-ready immunotherapy.
Sanofi invests heavily in multiple myeloma pipeline
Latest NewsSanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment.
Bio-Me raises NOK10m
Latest NewsOslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.